BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20135632)

  • 1. HIV-1 integrase inhibitors: 2007-2008 update.
    Ramkumar K; Serrao E; Odde S; Neamati N
    Med Res Rev; 2010 Nov; 30(6):890-954. PubMed ID: 20135632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.
    Voet AR; Maeyer MD; Debyser Z; Christ F
    Future Med Chem; 2009 Oct; 1(7):1259-74. PubMed ID: 21426102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics simulations of the HIV-1 integrase dimerization interface: guidelines for the design of a novel class of integrase inhibitors.
    Sippel M; Sotriffer CA
    J Chem Inf Model; 2010 Apr; 50(4):604-14. PubMed ID: 20230013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; QuiƱones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process.
    De Luca L; Gitto R; Christ F; Ferro S; De Grazia S; Morreale F; Debyser Z; Chimirri A
    Antiviral Res; 2011 Oct; 92(1):102-7. PubMed ID: 21767569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
    Pace P; Spieser SA; Summa V
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
    Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
    Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
    Hong H; Neamati N; Wang S; Nicklaus MC; Mazumder A; Zhao H; Burke TR; Pommier Y; Milne GW
    J Med Chem; 1997 Mar; 40(6):930-6. PubMed ID: 9083481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
    Petrocchi A; Jones P; Rowley M; Fiore F; Summa V
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4245-9. PubMed ID: 19523819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 integrase inhibitors: a review of their chemical development.
    Ingale KB; Bhatia MS
    Antivir Chem Chemother; 2011 Nov; 22(3):95-105. PubMed ID: 22095518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors.
    Dayam R; Sanchez T; Neamati N
    ChemMedChem; 2006 Feb; 1(2):238-44. PubMed ID: 16892356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to novel drug classes.
    Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
    Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the structural requirement for inhibiting HIV integrase: QSAR study.
    Dessalew N
    Acta Pharm; 2009 Mar; 59(1):31-43. PubMed ID: 19304556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 integrase inhibitors: 2005-2006 update.
    Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
    Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.